189 related articles for article (PubMed ID: 29663892)
1. Complement Components, C3 and C4, and the Metabolic Syndrome.
Copenhaver M; Yu CY; Hoffman RP
Curr Diabetes Rev; 2019; 15(1):44-48. PubMed ID: 29663892
[TBL] [Abstract][Full Text] [Related]
2. Relationships of complement components C3 and C4 and their genetics to cardiometabolic risk in healthy, non-Hispanic white adolescents.
Copenhaver MM; Yu CY; Zhou D; Hoffman RP
Pediatr Res; 2020 Jan; 87(1):88-94. PubMed ID: 31404919
[TBL] [Abstract][Full Text] [Related]
3. High expression of complement components in omental adipose tissue in obese men.
Gabrielsson BG; Johansson JM; Lönn M; Jernås M; Olbers T; Peltonen M; Larsson I; Lönn L; Sjöström L; Carlsson B; Carlsson LM
Obes Res; 2003 Jun; 11(6):699-708. PubMed ID: 12805391
[TBL] [Abstract][Full Text] [Related]
4. Complement C3 and C4, but not their regulators or activated products, are associated with incident metabolic syndrome: the CODAM study.
Xin Y; Hertle E; van der Kallen CJH; Schalkwijk CG; Stehouwer CDA; van Greevenbroek MMJ
Endocrine; 2018 Dec; 62(3):617-627. PubMed ID: 30132263
[TBL] [Abstract][Full Text] [Related]
5. Plasma complement C3 levels are associated with insulin secretion independently of adiposity measures in non-diabetic individuals.
Fiorentino TV; Hribal ML; Andreozzi F; Perticone M; Sciacqua A; Perticone F; Sesti G
Nutr Metab Cardiovasc Dis; 2015 May; 25(5):510-7. PubMed ID: 25813686
[TBL] [Abstract][Full Text] [Related]
6. The Emerging Role of Complement C3 as A Biomarker of Insulin Resistance and Cardiometabolic Diseases: Preclinical and Clinical Evidence.
Ursini F; Abenavoli L
Rev Recent Clin Trials; 2018 Jan; 13(1):61-68. PubMed ID: 29189176
[TBL] [Abstract][Full Text] [Related]
7. C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors.
Nilsson B; Hamad OA; Ahlström H; Kullberg J; Johansson L; Lindhagen L; Haenni A; Ekdahl KN; Lind L
Eur J Clin Invest; 2014 Jun; 44(6):587-96. PubMed ID: 24754458
[TBL] [Abstract][Full Text] [Related]
8. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.
Tüzün E; Scott BG; Goluszko E; Higgs S; Christadoss P
J Immunol; 2003 Oct; 171(7):3847-54. PubMed ID: 14500686
[TBL] [Abstract][Full Text] [Related]
9. Acylation stimulating protein but not complement C3 associates with metabolic syndrome components in Chinese children and adolescents.
Wamba PC; Mi J; Zhao XY; Zhang MX; Wen Y; Cheng H; Hou DQ; Cianflone K
Eur J Endocrinol; 2008 Dec; 159(6):781-90. PubMed ID: 18805911
[TBL] [Abstract][Full Text] [Related]
10. The allogeneic T and B cell response is strongly dependent on complement components C3 and C4.
Marsh JE; Farmer CK; Jurcevic S; Wang Y; Carroll MC; Sacks SH
Transplantation; 2001 Oct; 72(7):1310-8. PubMed ID: 11602861
[TBL] [Abstract][Full Text] [Related]
11. Complement C4 is protective for lupus disease independent of C3.
Einav S; Pozdnyakova OO; Ma M; Carroll MC
J Immunol; 2002 Feb; 168(3):1036-41. PubMed ID: 11801636
[TBL] [Abstract][Full Text] [Related]
12. Recombinant acylation stimulating protein administration to C3-/- mice increases insulin resistance via adipocyte inflammatory mechanisms.
Munkonda MN; Lapointe M; Miegueu P; Roy C; Gauvreau D; Richard D; Cianflone K
PLoS One; 2012; 7(10):e46883. PubMed ID: 23056509
[TBL] [Abstract][Full Text] [Related]
13. Medical Records-Based Genetic Studies of the Complement System.
Khan A; Shang N; Petukhova L; Zhang J; Shen Y; Hebbring SJ; Moncrieffe H; Kottyan LC; Namjou-Khales B; Knevel R; Raychaudhuri S; Karlson EW; Harley JB; Stanaway IB; Crosslin D; Denny JC; Elkind MSV; Gharavi AG; Hripcsak G; Weng C; Kiryluk K
J Am Soc Nephrol; 2021 Aug; 32(8):2031-2047. PubMed ID: 33941608
[TBL] [Abstract][Full Text] [Related]
14. Complement component 3 (C3) as a biomarker for insulin resistance after bariatric surgery.
Bratti LOS; do Carmo ÍAR; Vilela TF; Wopereis S; de Moraes ACR; Borba BGM; Souza LC; Filippin-Monteiro FB
Clin Biochem; 2017 Jun; 50(9):529-532. PubMed ID: 28188738
[TBL] [Abstract][Full Text] [Related]
15. C4, BF, C3 allele distribution and complement activity in healthy aged people and centenarians.
Bellavia D; Fradà G; Di Franco P; Feo S; Franceschi C; Sansoni P; Brai M
J Gerontol A Biol Sci Med Sci; 1999 Apr; 54(4):B150-3. PubMed ID: 10219002
[TBL] [Abstract][Full Text] [Related]
16. Sex-Specific Associations Between Complement Component 3 and Component 4 Levels and Metabolic Syndrome in an Adult Population.
Meng G; Li H; Li Y; Zhang Q; Liu L; Wu H; Xia Y; Bao X; Gu Y; Su Q; Fang L; Yang H; Yu F; Shi H; Sun S; Wang X; Zhou M; Jia Q; Song K; Chang H; Wu Y; Niu K
Metab Syndr Relat Disord; 2018 Apr; 16(3):143-149. PubMed ID: 29596043
[TBL] [Abstract][Full Text] [Related]
17. Complement C3 and cleavage products in cardiometabolic risk.
Onat A; Can G; Rezvani R; Cianflone K
Clin Chim Acta; 2011 Jun; 412(13-14):1171-9. PubMed ID: 21419112
[TBL] [Abstract][Full Text] [Related]
18. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events.
Palikhe A; Sinisalo J; Seppänen M; Haario H; Meri S; Valtonen V; Nieminen MS; Lokki ML
Am J Cardiol; 2007 Apr; 99(7):890-5. PubMed ID: 17398178
[TBL] [Abstract][Full Text] [Related]
19. C3 and C4 gene expression and interferon-gamma-mediated regulation in human glomerular mesangial cells.
Sacks S; Zhou W; Campbell RD; Martin J
Clin Exp Immunol; 1993 Sep; 93(3):411-7. PubMed ID: 8370168
[TBL] [Abstract][Full Text] [Related]
20. Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice.
Sheerin NS; Springall T; Carroll MC; Hartley B; Sacks SH
Clin Exp Immunol; 1997 Dec; 110(3):403-9. PubMed ID: 9409643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
